Clinical relevance of microparticles from platelets and megakaryocytes

Joseph E Italiano1, Albert T A Mairuhu, Robert Flaumenhaft

  • 1Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. jitaliano@rics.bwh.harvard.edu

Abstract

Insights

Platelet microparticles, abundant in circulation, are increasingly understood to originate from megakaryocytes and activated platelets. These particles act as crucial delivery systems in various physiological and pathological processes, including immunity and inflammation.

Area of Science:

  • Hematology
  • Cell Biology
  • Immunology

Background:

  • Platelet microparticles (PMPs) are the most common circulating microparticle subtype, identified over 40 years ago.
  • Despite their abundance, fundamental aspects of PMP formation and their roles in disease remain incompletely understood at the cellular and molecular levels.

Purpose of the Study:

  • To review the mechanisms of platelet microparticle generation.
  • To evaluate the current understanding of the clinical relevance of platelet microparticles.

Main Methods:

  • This review synthesizes recent evidence on PMP formation and function.
  • It examines studies elucidating PMP involvement in various disease states.

Main Results:

  • The majority of circulating CD41 microparticles in healthy individuals originate from megakaryocytes.
  • PMPs also form from activated platelets due to loss of cytoskeleton-membrane adhesion, prevalent in many diseases.
  • Platelet microparticles function as transport systems for bioactive molecules, influencing hemostasis, thrombosis, inflammation, malignancy, infection, angiogenesis, and immunity.
  • Mechanisms of PMP participation in diseases like rheumatoid arthritis have been clarified.

Conclusions:

  • Further research on PMP generation and their function as transcellular delivery systems is essential.
  • Understanding PMPs can advance knowledge of microparticle physiology and lead to novel therapeutic strategies for specific diseases.